The lack of effective therapy for glioblastoma multiforme (GBM) 
Introduction

The lack of effective therapy for glioblastoma multiforme (GBM), which remains one of the most challenging solid cancers to treat because of its highly proliferative and invasive nature, has necessitated identification of new treatment strategies. Histone deacetylase (HDAC) inhibitors with potent chemopreventive and chemotherapeutic activities inhibit tumour development through inhibition of cell proliferation, induction of cell-cycle arrest and apoptosis of cancer cells
. HDAC inhibition has been reported to promote growth arrest in glioma cells [2] [3] [4] . Scriptaid, a recently identified HDAC inhibitor [5] , arrests growth of endometrial and ovarian cancer cells [6] . As HDAC inhibitors are emerging as a promising anti-neoplastic strategy, we assessed the effect of scriptaid on glioma cell apoptosis. [7] . Importantly, JNK activation potently sensitizes glioma cells to apoptosis [8] by triggering apoptotic cascades [9] . JNK is activated by MAP kinase kinases (MAPKK) , and the GTP-binding protein, Ras, plays a crucial role in MAP kinase activation [10] . We have recently demonstrated that increased Ras activation can play an active role in glioma cell apoptosis [11] , and the pro-apoptotic effects of Ras are mediated by MAPK [12] . As HDAC inhibitors are known to induce cell death selectively in cells that harbour activated kRasV12 [13] , we evaluated the ability of scriptaid to affect Ras/JNK activity in glioma cells. HDAC inhibitors are also known to suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells [14] and JNK is a key regulator of telomerase activity [15] . Moreover, telomerase inhibition is a promising approach for the targeting GBMs [16] and HDAC inhibitor has been shown to inhibit telomerase activity and hTERT expression in brain cancer cells [17] . Therefore, the ability of scriptaid to effect telomerase activity was also investigated. 
Activation of c-Jun-NH2-terminal kinase/stress-activated protein kinase (JNK) plays a functional role in HDAC inhibitor-mediated apoptosis
Here, we show that scriptaid-induced JNK activation plays a crucial role in triggering glioma cell death. Although scriptaid affected the expression of molecules involved in cell-cycle regulation and DNA damage repair response in a JNK-dependent manner, it decreased telomerase activity independent of JNK activation. Our results indicate that scriptaid not only (i) induces glioma cell death and inhibit their proliferation but also (ii) decreases telomerase activity.
Cell culture and treatment
Glioblastoma cell lines LN229 and T98G obtained from American
Determination of cell viability
Cell viability was assessed using the [3-(4,5- 
Assay of caspase-3 activity
The Colorimetric Assay Kit for caspases-3 (Sigma) was used to determine the enzymatic activity of caspase-3 in glioma cells treated with scriptaid, as described previously [18] . 
Western blot analysis
Proteins from whole cell lysates and nuclear extracts were isolated as described previously [19] . [19] .
Comet assay
Comet assay was performed as described previously [20] . 
Flow cytometric analysis of DNA content
To determine the effect of scriptaid on glioma cell-cycle progression, FACS analysis of DNA content was performed as described [18] . [18] . 
Telomerase activity
Measurement of Ras activity
The Ras activity was performed using a commercially available Ras activation assay kit purchased from Upstate Biotechnology (Temecula, CA, USA), as described previously [11] . (Fig. 1B) . Because the activation of caspase-3-like proteases is crucial in apoptotic cell death [21] , these results suggest that scriptaid induces apoptosis in glioma cells. [25] . Moreover, HDAC inhibitors have been reported to induce phosphorylation of H2AX in leukaemia cells [26] . Because a decrease in cMyc expression was observed in scriptaid-treated glioma cells, we determined the expression of ␥-H2AX in these cells. The expression of ␥-H2AX was elevated following scriptaid treatment (Fig. 4A) , in a dose-dependent manner. The levels of total H2AX were unaffected by scriptaid treatment (Fig. 4A) .
Results
Scriptaid induces apoptosis in glioma cells
Scriptaid decreases HDAC activity and increases acetylation of H3 and H4 histone in glioma cells
Because scriptaid is a known HDAC inhibitor, we investigated its ability to regulate the HDAC activity in glioma cells. A significant
Fig. 1 Scriptaid induces apoptosis in glioma cells. (A) Scriptaid decreases viability of glioma cells in a dose
The ability to repair DNA damage is essential to cell survival because maintained DNA breaks induce apoptosis [27] . As expression of DNA damage repair protein ␥-H2AX was elevated in scriptaid-treated cells, comet assay was performed to determine the effect of scriptaid on glioma cells. Treatment with scriptaid resulted in increase in comet tail length as compared to untreated control, suggesting an induction of DNA damage by scriptaid (Fig. 4B) .
Scriptaid increases Ras expression and activity in glioma cells
Ras induces DNA damage signalling response [28] and cells that senesce in response to oncogenic Ras accumulate DNA damage foci [29] . Disruption of cooperation of Ras and cMyc promotes growth arrest of neuroblastoma cells [30] . Moreover, oncogenic Ras promotes HDAC inhibitor butyrate-induced apoptosis [31] . (Fig. 5A) . [32] . The levels of activated Ras were dramatically elevated in glioma cells at 1 hr after scriptaid treatment (Fig. 5B ).
Because scriptaid-triggered apoptosis was concomitant with decrease in cMyc and increase in ␥-H2AX, we investigated the contribution of Ras in scriptaid-induced apoptosis. Western blot analysis demonstrated an increase in Ras
Fig. 2 Scriptaid decreases HDAC activity and increases histone acetylation of glioma cells. (A) Scriptaid treatment decreases HDAC activity in glioma cells. HDAC activity of scriptaid-treated LN229 and T98G cells was performed using HDAC activity assay kit according to manufacturer's instruction. A decrease in HDAC activity in LN229 and T98G cells upon exposure to increasing dose of scriptaid was observed. Values represent the means Ϯ SEM from three independent experiments. * Significant decrease from control (P Ͻ 0.05). (B) Scriptaid induces H3 and H4 hyperacetylation in glioma cells. Western blot analysis was performed on nuclear extracts obtained from LN229 and T98G cells treated with scriptaid. An increase in H3 and H4 acetylation was observed upon exposure of glioma cells to increasing concentration of scriptaid. A representative blot is shown from three independent experiments with identical results. Blots were reprobed for ␤-actin to establish equivalent loading. expression in LN229 and T98G cells upon increasing exposure to scriptaid
As Ras levels were elevated in scriptaid-treated cells, we next investigated the effect of scriptaid on Ras activity. Lysates from cells grown in the presence or absence of scriptaid for different intervals of time were subjected to a Ras-GTP pull-down assay
Importantly, this heightened level of activated Ras was sustained even at 24 hrs post-treatment with scriptaid (Fig. 5B). Thus, scriptaid-induced apoptosis of glioma cells was concurrent with increased Ras activity.
Pro-apoptotic effects of scriptaid are mediated by increased Ras activation
Oncogenic Ras induces apoptosis [33] and inducible expression of kRasV12 sensitizes cells to HDAC inhibitor-induced apoptosis [13] . (Fig. 5C ).
We therefore determined whether elevated Ras was critical in scriptaid-induced cell death. Glioma cells were transfected with the expression plasmid coding for constitutively active Ras (RasV12) in the absence or the presence of scriptaid. The decrease in cell viability observed when glioma cells were treated with scriptaid was further decreased in cells expressing the constitutive active Ras (RasV12). T98G cell viability was reduced from 87, 77 and 54% in
mock-transfected cells to 72, 51 and 37% in RasV12-transfected cells, upon treatment with 5, 10 and 20 M concentration of scriptaid, respectively (Fig. 5C). Similar trend was observed in LN229 cells (Fig. 5C). However, glioma cells transfected with dominant negative RasN17 were only marginally protected from scriptaid-induced apoptosis as compared to untransfected cells (data not shown). This suggests that RasN17 cannot completely override scriptaid-induced increase in Ras activity. To demonstrate that transfection with constitutive RasV12 elevates Ras activity, Ras GTPase activity was determined in glioma cells transfected with RasV12 or control vector in the presence or absence of 20 M scriptaid. Although transfection with constitutive RasV12 resulted in a increase in Ras activity as compared to the mock-transfected control, the effect was more pronounced in scriptaid-treated cells
Pro-apoptotic effects of Ras are mediated by the JNK pathway
The pro-apoptotic effects of Ras are mediated by the MAPK pathway [12] . Because HDAC inhibitors induce apoptosis in leukaemia cells through JNK activation [7] , we investigated the status of p38MAPK and JNK activation in scriptaid-treated glioma cells. An elevation in JNK and the p38MAPK phosphorylation was observed in glioma cells upon increasing exposure to scriptaid (Fig. 6A) , as compared to the untreated control. Treatment with scriptaid had no effect on the total p38MAPK and JNK levels in glioma cells (Fig. 6A) .
As p38MAPK and JNK activity was elevated in scriptaid-treated cells, the viability of scriptaid-treated glioma cells in the presence and absence of SB203580 and SP600125-respective inhibitors of p38MAPK and JNK was determined. Treatment of glioma cells with scriptaid in the presence of SB203580 had no effect on scriptaid-induced glioma cell death (data not shown).
Although inhibition of p38MAPK had no effect in reversing scriptaidinduced cell death, JNK inhibition significantly decreased scriptaid-induced apoptosis (Fig. 6B) (Fig. 6B) . This suggested the involvement of 
pathways other than that mediated by increased JNK activation, which triggers the anti-proliferative effect of scriptaid. As we have recently reported that ERK activation plays an active role in mediating Miltefosine-induced apoptosis of glioma cells [11], we determined the status of ERK phosphorylation in scriptaid-treated cells.
Treatment with scriptaid had no effect on ERK phosphorylation, which remained comparable to control levels (data not shown).
Scriptaid-induced changes in cell-cycle regulatory and DNA damage response repair proteins are JNK dependent
Inhibition of tumour cell-cycle arrest through JNK activation has been reported [34] . Because JNK activation is involved in scriptaid-induced glioma cell death, we investigated whether JNK pathway modulate cell-cycle regulatory proteins by determining p21 and p27 expression in glioma cells treated with scriptaid in the presence and absence of JNK inhibitors. The increased p21 and p27 expression observed upon scriptaid treatment was reversed in the presence of JNK inhibitor (Fig. 6) . Ras induces DNA damage signalling response [28] and JNK activation radiosensitizes colon carcinoma cells through enhanced DNA damage [35] . Because increased Ras and JNK activation was observed in scriptaid-treated cells, we determined the expression of ␥-H2AX in cells treated with scriptaid in the presence and absence of JNK inhibitors. The elevated levels of ␥H2AX observed in scriptaid-treated cells were abrogated to control levels in the presence of JNK inhibitor (Fig. 7) (Fig. 8) . As inhibition of telomerase activity has been suggested to cause cell death in glioma [16] , the ability of scriptaid to abrogate telomerase activity may subsequently result in reduced glioma cell proliferation and cell death. [38] .
HDAC inhibitors have been reported to increase ␥H2AX expression in leukaemic cells [26] , and H2AX is a target of JNK signalling pathway required for apoptotic DNA fragmentation [39] . H2AX is also involved in cellular apoptosis as JNK/H2AX pathway cooperates with the caspase-3 pathway to induce apoptosis [40] . It is possible that scriptaid-mediated JNK-dependent increase in H2AX expression co-operates with increased caspase-3 to induce apoptosis.
HDAC inhibitor suppresses telomerase activity in prostate cancer cells [14] and JNK is a key regulator of telomerase activity [15] . Moreover, dysfunctional telomeres activates DNA damage checkpoint [41] and cellular response to telomere dysfunction is governed by proteins such as ␥-H2AX [42] . We also report for the first time that scriptaid inhibits telomerase activity in JNK-independent manner. The ability of scriptaid to inhibit telomerase activity may lead to telomere dysfunction and might contribute to apoptosis. The telomerase activity inhibition, coupled with its ability to induce apoptosis and regulate DNA damage response by scriptaid, warrants further investigation of its role as a promising therapeutic strategy in GBM. 
